Literature DB >> 27424148

Stem cell therapy emerging as the key player in treating type 1 diabetes mellitus.

Aruna V Vanikar1, Hargovind L Trivedi2, Umang G Thakkar3.   

Abstract

Type 1 diabetes mellitus (T1DM) is an autoimmune disease causing progressive destruction of pancreatic β cells, ultimately resulting in loss of insulin secretion producing hyperglycemia usually affecting children. Replacement of damaged β cells by cell therapy can treat it. Currently available strategies are insulin replacement and islet/pancreas transplantation. Unfortunately these offer rescue for variable duration due to development of autoantibodies. For pancreas/islet transplantation a deceased donor is required and various shortfalls of treatment include quantum, cumbersome technique, immune rejection and limited availability of donors. Stem cell therapy with assistance of cellular reprogramming and β-cell regeneration can open up new therapeutic modalities. The present review describes the history and current knowledge of T1DM, evolution of cell therapies and different cellular therapies to cure this condition.
Copyright © 2016 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  adult stem cells; induced pluripotent stem cells; insulin-secreting cells; mesenchymal stromal cells; stem cell therapy; type 1 diabetes mellitus

Mesh:

Substances:

Year:  2016        PMID: 27424148     DOI: 10.1016/j.jcyt.2016.06.006

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  9 in total

1.  Uterine Cells Improved Ovarian Function in a Murine Model of Ovarian Insufficiency.

Authors:  Andres Reig; Ramanaiah Mamillapalli; Alexis Coolidge; Joshua Johnson; Hugh S Taylor
Journal:  Reprod Sci       Date:  2019-09-17       Impact factor: 3.060

Review 2.  The journey of islet cell transplantation and future development.

Authors:  Anissa Gamble; Andrew R Pepper; Antonio Bruni; A M James Shapiro
Journal:  Islets       Date:  2018-02-05       Impact factor: 2.694

3.  Human urine-derived stem cells play a novel role in the treatment of STZ-induced diabetic mice.

Authors:  Tianxue Zhao; Deng Luo; Yun Sun; Xin Niu; Yang Wang; Chen Wang; Weiping Jia
Journal:  J Mol Histol       Date:  2018-04-19       Impact factor: 2.611

4.  Efficacy and Safety of Stem Cell Therapy for T1DM: An Updated Systematic Review and Meta-Analysis.

Authors:  Shi-Yi Sun; Yun Gao; Guan-Jian Liu; Yong-Kun Li; Wei Gao; Xing-Wu Ran
Journal:  J Diabetes Res       Date:  2020-10-10       Impact factor: 4.011

Review 5.  Medicinal plants in the adjunctive treatment of patients with type-1 diabetes: a systematic review of randomized clinical trials.

Authors:  Farzaneh Barzkar; Hamid Reza Baradaran; Mohammad Ebrahim Khamseh; Roya Vesal Azad; Jalil Koohpayehzadeh; Yousef Moradi
Journal:  J Diabetes Metab Disord       Date:  2020-09-22

Review 6.  Functional maturation of immature β cells: A roadblock for stem cell therapy for type 1 diabetes.

Authors:  Zi-Yi Sun; Ting-Yan Yu; Fang-Xu Jiang; Wei Wang
Journal:  World J Stem Cells       Date:  2021-03-26       Impact factor: 5.326

Review 7.  Pancreatic transplant surgery and stem cell therapy: Finding the balance between therapeutic advances and ethical principles.

Authors:  Martina Padovano; Matteo Scopetti; Federico Manetti; Donato Morena; Davide Radaelli; Stefano D'Errico; Nicola Di Fazio; Paola Frati; Vittorio Fineschi
Journal:  World J Stem Cells       Date:  2022-08-26       Impact factor: 5.247

8.  Tailored generation of insulin producing cells from canine mesenchymal stem cells derived from bone marrow and adipose tissue.

Authors:  Watchareewan Rodprasert; Sirirat Nantavisai; Koranis Pathanachai; Prasit Pavasant; Thanaphum Osathanon; Chenphop Sawangmake
Journal:  Sci Rep       Date:  2021-06-11       Impact factor: 4.379

Review 9.  The modulation of enzyme indoleamine 2,3-dioxygenase from dendritic cells for the treatment of type 1 diabetes mellitus.

Authors:  Débora Moitinho Abram; Luis Gustavo Romani Fernandes; Antônio Celso Saragossa Ramos Filho; Patrícia Ucelli Simioni
Journal:  Drug Des Devel Ther       Date:  2017-07-24       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.